| Date Filed | Type | Description |
| 11/05/2020 |
GN
| Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights |
| 10/01/2020 |
GN
| Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Positive Data from Ongoing Open Label Arm of Resmetirom 52 Week Phase 3 MAESTRO-NAFLD-1 Trial |
| 09/03/2020 |
GN
| Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial |
| 08/26/2020 |
GN
| Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020 |
| 04/14/2020 |
GN
| Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction |
| 12/18/2019 |
GN
| Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (NASH/NAFLD (non-alcoholic fatty liver disease)) |
| 12/10/2019 |
GN
| Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock |
| 11/11/2019 |
GN
| Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH) |
| 11/06/2019 |
GN
| Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights |
| 08/07/2019 |
GN
| Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights |
| 07/02/2019 |
GN
| Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors |
| 06/04/2019 |
GN
| Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences |
| 05/15/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of Madrigal Pharmaceuticals, Inc. |
| 05/08/2019 |
GN
| Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights |
| 04/08/2019 |
GN
| Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019 |
| 03/28/2019 |
GN
| Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation |
| 02/27/2019 |
GN
| Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights |
| 11/06/2018 |
GN
| Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events |
| 10/19/2018 |
GN
| Research Report Identifies Brookfield Asset Management, Becton, Dickinson, IPG Photonics, ASML Holding N.V, American National Insurance, and Madrigal Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement |
| 06/06/2018 |
GN
| Madrigal Pharmaceuticals Prices Public Offering of Common Stock |
| 06/05/2018 |
GN
| Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock |
| 05/31/2018 |
GN
| Madrigal's MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial |
| 05/29/2018 |
GN
| Report: Exploring Fundamental Drivers Behind Vivint Solar, Peapack-Gladstone Financial, Madrigal Pharmaceuticals, Univest Corporation of Pennsylvania, Amtech, and Lithia Motors — New Horizons, Emerging Trends, and Upcoming Developments |
| 05/08/2018 |
GN
| Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements |
| 04/04/2018 |
GN
| Recent Analysis Shows Multi-Color, Madrigal Pharmaceuticals, SPX, AngioDynamics, Atara Biotherapeutics, and Quanex Building Products Market Influences — Renewed Outlook, Key Drivers of Growth |
| 03/13/2018 |
GN
| Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196 |
| 02/05/2018 |
GN
| Consolidated Research: 2018 Summary Expectations for Kimball Electronics, Madrigal Pharmaceuticals, American Railcar Industries, H&R Block, Biogen, and Equinix — Fundamental Analysis, Key Performance Indications |
| 01/30/2018 |
GN
| Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress™ 2018 |
| 12/18/2017 |
GN
| Madrigal Pharmaceuticals Prices Public Offering of Common Stock |
| 12/06/2017 |
GN
| Madrigal's MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial |
| 10/23/2017 |
GN
| Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead ß-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver Meeting |
| 08/10/2017 |
GN
| Madrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results |
| 06/21/2017 |
GN
| Madrigal Pharmaceuticals Announces $35 Million Private Placement Offering |
| 05/11/2017 |
GN
| Madrigal Pharmaceuticals Reports 2017 First Quarter Financial Results |
|